Sudemycin K
Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS) [1].
Product Specifications
CAS Number
2071636-70-7
UNSPSC
12352005
Target
SF3B1
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
C[C@H](NC(C(C)C)=O)/C=C\C(NC1CCC(C/C=C(C)/C=C/[C@@H](OC(C)(C)C2)C[C@@]32CO3)CC1)=O
Molecular Formula
C29H46N2O4
Molecular Weight
486.69
References & Citations
[1]Makowski K, et al. Sudemycin K: A Synthetic Antitumor Splicing Inhibitor Variant with Improved Activity and Versatile Chemistry. ACS Chem Biol. 2017 Jan 20;12 (1) :163-173.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC880050-500 1x 500 µL
IgA Secretory Component (SC05), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC470352-100 1x 100 µL
CD31 / PECAM-1 (158-2B3), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880696-100 1x 100 µL
Cytokeratin 10/13 (DE-K13), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details